No Data
No Data
CytoSorbents' Blood Purification Device Gets Approval
CytoSorbents (CTSO) said Monday it has received the China Taiwan Food and Drug Administration's authorization for its blood purification device CytoSorb.
Express News | Cytosorbents Announces Launch and Immediate Availability of Purifi™ Blood Pump in European Union
Here's Why Shareholders Should Examine Cytosorbents Corporation's (NASDAQ:CTSO) CEO Compensation Package More Closely
B. Riley Securities: Reiterated CytoSorbents (CTSO.US) rating and adjusted from buy to buy rating, target price of $3.00.
B. Riley Securities: Reiterated CytoSorbents (CTSO.US) rating and adjusted from buy to buy rating, target price of $3.00.
B. Riley Securities Reiterates Buy on CytoSorbents, Maintains $3 Price Target
B. Riley Securities analyst Yuan Zhi reiterates CytoSorbents with a Buy and maintains $3 price target.
Cytosorbents First Quarter 2024 Earnings: In Line With Expectations